Biotech | January 04, 2022
USFDA grants ILiAD Biotechnologies Fast Track Designation for pertussis vaccine
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Heart failure affects an estimated 64.3 million people worldwide
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Subscribe To Our Newsletter & Stay Updated
